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Abstract
Cerebral cavernous malformations (CCM) are vascular anomalies caused by mutations in genes
encoding KRIT1, OSM and PDCD10 proteins causing hemorrhagic stroke. We examine
proteomic change of loss of CCM gene expression. Using human umbilical vein endothelial cells,
label-free differential protein expression analysis with multidimensional liquid chromatography/
tandem mass spectrometry was applied to three CCM protein knockdown cell lines and two
control cell lines: ProteomeXchange identifier PXD000362. Principle component and cluster
analyses were used to examine the differentially expressed proteins associated with CCM. The
results from the five cell lines revealed 290 and 192 differentially expressed proteins (p < 0.005
and p < 0.001, respectively). Most commonly affected proteins were cytoskeleton-associated
proteins, in particular myosin-9. Canonical genetic pathway analysis suggests that CCM may be a
result of defective cell–cell interaction through dysregulation of cytoskeletal associated proteins.
Conclusion—The work explores signaling pathways that may elucidate early detection and
novel therapy for CCM.
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Cerebral cavernous malformation (CCM) is an inherited vascular disorder predisposing
individuals to hemorrhagic stroke. CCM affects about 0.5% of the US general population,
with a higher prevalence in the Hispanic population [1]. CCM is usually not known to
affected individuals until the clinical symptoms occur [2,3]. These symptoms usually do not
manifest until the third or fourth decade of the individual’s life. Ruptured CCM lesions lead
to stroke, as each new CCM lesion increases the seizure rate by 2.4% per year. CCM is also
associated with seizures, recurrent headaches and focal neurological defects [2,4].
Therefore, it is important to be able to detect this genetic abnormality earlier in life to
prevent the CCM lesions that result in major hemorrhagic stroke [5]. CCM results from the
loss of function in a CCM protein due to a genetic mutation. Recently, three genes were
identified associated with CCM conditions: CCM1 (krev interaction trapped 1 [KRIT1]),
CCM2 (osmosensing scaffold for MEKK3 [OSM]) and CCM3 (programmed cell death 10
[PDCD10]) that lead to the formation of CCM lesions [6–11]. These three CCM genes
interact to form a protein complex in the cell. Knockdown of any CCM gene leads to
defective in vitro endothelial tube formation mimicking in CCM clinical lesions [12].
The CCM1 gene encodes the KRIT1 protein that interacts with the Krev-1/rap1a signaling
pathway. Krev-1/rap1a is part of the family of Ras GTPase enzymes and functions as a
tumor suppressor [13]. The specific function of the KRIT1 protein is unknown [14]. KRIT1
is composed of three ankyrin domains and a C-terminal FERM domain. These domains are
known to interact with actin. KRIT1 functionality also stems from its interaction with
integrin cytoplasmic domain-associated protein (ICAP1α). KRIT1 contains NPXY motifs
on its N-terminal that is required for interaction with ICAP1α. ICAP1α also interacts with
β1 integrin. It has been shown that induced expression of KRIT1 decreases the interaction of
ICAP1α and β1 integrin. Therefore, KRIT1 may function as a competitive inhibitor and
regulator of β1 integrin–ICAP1α interaction [15].
The CCM2 gene encodes OSM, and has been identified as a critical regulator for endothelial
cell signaling and regulation [16,17]. OSM is located on chromosome 7p13 and is composed
of N-terminal (phosphotyrosine-binding domain) and a C-terminal, with no known structural
motifs [11]. OSM interacts with KRIT1’s NPXY motifs through its phosphotyrosine-binding
domain. OSM is a required scaffold for MEKK3-mediated p38 MAPK phosphorylation in
response to osmotic stress [16,17]. OSM also functions as a Smurf1 recruiter through a
Homologous to the E6-AP Carboxyl Terminus domain. CCM2 directs Smurf1 to a particular
region of the plasma membrane where it breaks down Ras homolog gene family, member A
(RhoA). This is critical, as increased RhoA protein levels result in tube formation
deficiencies [18].
The CCM3 gene encodes for PDCD10, a protein whose function is apoptosis through the
caspase 3 pathway [19]. PDCD10 comprises 212 amino acids with an N-terminal binding
site for serine/threonine kinase 25, the oxidant stress response enzyme [20]. This regulates
PDCD10 by phosphorylation [21]. This is essential for activating germinal center kinase III
MST4 following oxidative stress [22]. MST4 plays a critical role in the phosphorylation of
ERM proteins that protects cells from programmed cell death. Inactivation of PDCD10
impairs this phosphorylation, making it more susceptible to oxidative stress [22]. The
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binding of PDCD10 to OSM occurs independent of KRIT1/OSM interaction [23]. PDCD10
binds to specific phosphatidylinositols and interacts with phosphatidylinositol-3-kinase
(PI3K). Activation of PI3K by growth factors such as VEGF is critical to angiogenesis and
perhaps CCM development. The CCM complex that is formed by these three genes is
impaired by a genetic mutation of any one of the aforementioned genes [23].
This study utilized a systems biology approach to examine the global proteomic changes in
human umbilical vein endothelial cells (HUVEC). Systems biology approach shows novel
canonical pathways related to CCM knockdowns. These specific biomarkers have the
potential to serve as diagnostic and drug-therapy targets in those afflicted with CCM. This
work is a descriptive and discovery study aiming to define the novel pathways in CCM
development.
Methods
Cell lines & knockdown cell lines
Cell Culture and RNAi-bEND.3, and HUVECs cells were purchased from American type
culture collection. Lentiviral genespecific shRNAs in pLKO.1 backbone were obtained from
the University of North Carolina, Chapel Hill Lenti-shRNA Core Facility. Lentiviral
infection was performed according to the RNAi consortium protocol. The Lipofectamine
2000 system (Invitrogen) was used for transfection and cells were subsequently selected for
resistance with treatment by 4 µg/ml puromycin. Measurement by real-time PCR with CCM-
specific primers was used to ensure knockdown (Figure 1A–C). However, the commercially
available antibodies were not selective enough for all CCM proteins. Experiments were
conducted after 7 days of growth in selection media in order to ensure stable protein
knockdown. Off target effects were controlled for by use of multiple unique shRNAs for
each protein being knocked down, and an empty vector pLKO.1 construct was used as an
experimental control. bEND.3 cells were maintained in 10% FBS/DMEM and HUVECs in
3% FBS/DMEM; 4 µg/ml puromycin was used to maintain shRNA selection.
Differential protein expression by LC/MS/MS analysis
Samples were analyzed using a simultaneous label-free differential protein expression
approach using a Thermo LTQ Orbitrap system. The mass spectrometry (MS) data were
processed using Rosetta Elucidator (Rosetta Biosoftware, Seattle, WA, USA). Data
processing steps included data pre-processing (mass calibration), mass signal alignment,
protein database searching and identification using Mascot (matrix science) with SwissProt
human databases. Study results included data from five cell lines analyzed in triplicate (total
of 15 replicates). Data processing in Elucidator was performed in multiple steps that
included mass correction and mass signal alignment of detected signals, retention time
alignment of detected signals and feature selection, with features representing mass signals
detected within the study set. Quality control review of the aligned data indicated the mass
signals were correctly aligned in the Elucidator software.
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Data analysis & differential protein determination
When applicable, mass signals were annotated with the corresponding peptide and protein
information based on the database search results using a 1% false discovery rate cutoff. For
retention time alignment, mathematical adjustments are performed to time-align the same
detected signals across all samples. Quality control assessment of this retention time shift
indicates that all adjustments were <3 min.
Principal component analysis (PCA) was performed on the collected dataset to evaluate the
data for outliers and sample trends. Results from the unsupervised analysis suggest that the
samples differentiate by cell line based on the mass spectrometric patterns detected. An
error-weighted analysis of variance was used to determine mass patterns that correlated to
differentially expressed proteins between cell lines. Signals with a p < 0.01 were selected as
tentative markers, grouped according to the specific protein from which they originated and
summarized by protein. PCA plots demonstrating replicate reproducibility and sample
differences based on detected differentially expressed proteins are presented in (Figure 1D–
G). The proteomic data have been deposited to the ProteomeXchange Consortium [24] via
the PRoteomics IDEntifications database partner repository with the dataset identifier
PXD000362.
Western blot analysis
The total protein content in the each harvested cell line was measured using a Bradford
assay with bovine serum albumin as a standard. Samples in total of 40 mg of protein per gel
lane were subjected to SDS-PAGE on a 4–15% gradient gel. The separated proteins were
transferred to nitrocellulose membrane, and the membranes were probed with anti-human
myosin-9 (MYH-9) monoclonal mouse antibody (Abcam, Cambridge, MA, USA) and anti-
human elongation factor 1γ (EF1G) mouse monoclonal antibody (Abcam), respectively. The
dilution used for the primary antibodies was 1:10,000. Horseradish peroxidase-conjugated
goat polyclonal secondary antibody to mouse IgG (Abcam) was used at a 1:5000 dilution to
detect MYH-9 and EF1G. Enhanced chemiluminescence (Amersham Biosciences, Inc.,
Pittsburgh, PA, USA) was used to visualize detected bands (Figure 2).
Modeling using ingenuity pathway analysis
We used ingenuity pathways analysis (IPA; Ingenuity Systems, CA, USA) to evaluate if any
of the biological pathways or networks have any statistical significance based on proteomic
data [25]. Protein accessions from each cell line (1–4; knockdown CCM1, 2, 3 and mock
knockdown with p < 0.005) were imported into IPA. Focus proteins, mapped to
corresponding gene objects in the ingenuity pathways knowledgebase, found in IPA were
used to generate biological networks. IPA then built the networks with <35 proteins. For
each network, p-value (indicating the likelihood of the focus proteins in a network being
found together due to chance) and canonical pathway is calculated based on the fit of each
set of significant proteins [25–27].
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The proteomes of CCM knockdown cell lines
The CCM proteins were selectively inhibited using shRNA. The controls used were a wild-
type HUVEC cell line and a mock shRNA (pLKO.1-empty vector). The functional
deficiency resulting from cell line knockdown was determined using an in vitro tube
formation assay [12]. The cell lines figures are designated cell line 1 (knockdown CCM1),
cell line 2 (knockdown CCM2), cell line 3 (knockdown CCM3), cell line 4 (wild-type
HUVEC) and cell line 5 (mock knockdown). Knockdown of each CCM cell line inhibited
endothelial tube formation. Each CCM cell line knockdown resulted in a similar incomplete
endothelial tube phenotype. However, the specific proteomic profile changes were unique
among each individual CCM cell line. To compare the proteomic changes between the five
cell lines, a label-free differential expression LC/MS/MS technique was used to quantify the
level of protein expression relative among the five cell lines. The amount of protein was
standardized to allow comparison of each cell line. The MS data were collected in five
biological triplicates for each cell line (n = 15 total), each cell line grown in triplication.
Data processing in Elucidator was performed in multiple steps that included mass correction
and mass signal alignment of detected signals, retention time alignment of detected signals
and feature selection, with features representing mass signals detected within the study set.
The MS analytical results were processed using the Rosetta Elucidator software. When
applicable, mass signals were annotated with the corresponding peptide and protein
information based on the database search results using a 1% false discovery rate cutoff. The
results indicated that each of the five cell lines was differentiated by its MS patterns.
Differential expression of each cell line was plotted and analyzed using two different p
values (p < 0.005 and 0.001) for PCA (Figure 1D & E). PCA analysis on the dataset
demonstrated cell line trends and evaluated the data for outliers. Cell line data from the
Thermo LTQ Orbitrap system was processed and resulted in the detection of 511 proteins.
The differentially expressed proteomic profiles are shown in the cluster heat map. The
results from the five cell lines revealed 290 and 192 differentially expressed proteins (p <
0.005 and 0.001, respectively). PCA shows clear separation of the proteomic profiles from
five cell lines. Cluster analysis shows differential expression of each protein (Figure 1F &
G). The expression of proteins including MYH-9 and EF1G were detected using western
blot analysis (Figure 2). Most signaling pathways presented here have been shown to be
related to CCM. We chose to only present the MYH-9 and EF1G data in this manuscript,
since it had not been previously presented.
Canonical pathway & functional analysis
From the differentially expressed proteins (analysis of variance; p < 0.005), we created a
ratio for each protein from each CCM cell line knockdown: CCM1, CCM2, CCM3 and
mock with respect to wild type using IPA. The fold change information, up and
downregulation, was added based on that ratio calculation. An evaluation of the biological
functions and diseases between the differentially expressed proteins and wild type was made
Figures 3–5; Supplementary Figures 1 & 2 (supplementary material can be found online at
www.informahealthcare.com/suppl/10.1586/14789450.2014.896742). This evaluation
included signaling pathways controlling protein translation (EIF2, elF4/p70S6K),
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angiogenesis (mTOR, PI3K/AKT, 14-3-3 protein and VEGF), cell junctions (remodeling of
epithelial adherens junctions, epithelial adherens junction, tight junction), actin (actin
cytoskeleton, regulation of actin-based mobility by Rho) and others (protein ubiquitination,
hypoxia in cardiovascular system, calcium, etc.). We used IPA to examine important
biological functions (Supplementary Figures 3–5) including cellular growth and
proliferation, cell death and survival, hematological disease, inflammatory disease,
inflammatory response, cellular movement, cellular development, cellular assembly and
organization, cell-to-cell signaling and interaction and cellular function and maintenance.
Discussion
The CCM cell line knockdowns led to a similar in vitro phenotype that is believed to mirror
the CCM lesion in the brain [12]. The proteomic results show several common signaling
pathways are significant in CCM and indicate that a separate signaling pathway for each
CCM gene is present as incomplete endothelial tube formation is exhibited by the inhibition
of each CCM gene. Furthermore, the specific proteomic profile changes are unique among
each individual CCM cell line. The proteomic profile changes of the HUVEC cell lines were
explored further using a western blot analysis to confirm the protein expression identified by
MS. This supported the label-free differential protein expression analysis that used
multidimensional liquid chromatography/tandem mass spectrometry (2D-LC-MS/MS) that
explored the comprehensive proteomic profile changes due to cell line knockdown. The
Thermo Orbitrap proteomic analysis of the data includes nine proteins known to interact
with the CCM complex that were differentially expressed among the five cell lines [28].
There are proteomic changes in the majority of proteins interacting with actin and tubulin,
including elongation factor 1α, EF1G, T complex protein 1 subunit β, transgelin, cofilin and
MYH-9 (Table 1) [23,28–37]. It is important to note here that MYH-9 has not been reported
associated with CCM condition.
In addition to proteomic analysis, we used a systems biology approach to determine
signaling pathways related to the knockdown of CCM genes. Through the use of IPA we
compared each knockdown with the wild type and used the mock knockdown as our
negative control. IPA demonstrates the effects of knockdown as we can see the increased
signaling in EFIF2 and 14-3-3-mediated signaling (Supplementary Figure 1). These
signaling pathways suggest translational disruption even with the mock knockdown. Beside
the effects of the knockdown, we found four prominent groups of signaling pathways
including VEGF, actin, cell junction and CCM2/OSM-related pathways. The signaling
pathways are summarized in Figure 6.
The PI3K/AKT and VEGF signaling pathways (Figure 3A–C) are known to be related to
CCM3/PDCD10 and CCM2/OSM [23]. Inflammation and other stress factors related to
CCM [38] can activate VEGF receptors and consequently activate PI3K/AKT and possibly
mTOR pathways. Activation of VEGF is perhaps a starting point for CCM-regulated
signaling that controls actin stability and actin–tubulin interaction. Knockdown of CCM
proteins change the expression of several actin/tubulin-related proteins (Table 1;
Supplementary Table 1). Actin-related pathways including actin cytoskeleton signaling and
regulation of actin-based motility by Rho (Figure 4A & B) are potentially controlled by
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CCM complex signaling through CCM2/OSM [12,16,17]. The CCM complex is shown to
be important in actin stability and is related to RhoA and LIM kinase signaling [12].
Knockdown of RhoA in CCM cell line knockdown reverses the CCM phenotype and
restores in vitro endothelial tube formation perhaps through LIMK pathway [12]. Expression
of actin-stabilizing proteins such as cofilin and transgelin, in our proteomic analysis, is also
altered. Binding of cofilin and transgelin to actin stabilizes actin–tubulin complex and
therefore regulates cellular process formation and cell migration [39]. Changes in
cytoskeletal proteins as a result of CCM dysregulation can further disturb the cell–cell
interaction as seen in several dysregulation in cell junction signal (Figure 5A–E). Disrupted
cell junction and basement membrane are found in CCM lesions [40–43] and is thought to
contribute to leakage and hemorrhagic stroke [44]. CCM proteins, in particular CCM2/
OSM, are known to regulate cell stress response (hypoxia signaling, ubiquination and
calcium signaling) (Supplementary Figure 2). Osmotic stress and possibly other stresses
may require OSM in MEKK3/MKK3 regulation of p38 activation [16]. Note that our
systems biology analysis in relation to disease pathways suggest that CCM2/OSM and
CCM3/PDCD10 knockdown may have more severe effects compared with CCM1/KRIT1 in
hematologic diseases and inflammatory disease (Supplementary Figure 5). CCM3
knockdown has the greatest effect in inflammatory response. This may link CCM3
mutations, the rarest but most severe form of CCM, to inflammatory responses and perhaps
to CCM3-mediated VEGF/mTOR/PI3K/AKT signaling. It is interesting to see that the
knockdown of CCM2/OSM has the most significant effect with respect to cellular
movement, cellular function and maintenance and cell growth and proliferation
(Supplementary Figure 3). This may be the result of direct interaction between OSM and
actin. Also, knockdown of CCM2 and CCM3 has the greatest effect on cell death and
survival (Supplementary Figure 4). PDCD10 is known for its apoptotic function. This again
suggests that perhaps OSM functions more closely to PDCD10 than KRIT1. We previously
suggested that OSM has direct interactions with KRIT1 and PDCD10. However, there is no
known direct interaction between PDCD10 and KRIT1 [23].
Conclusion
Genetic mutations of any of the CCM genes resulted in a similar incomplete in vitro
endothelial tube formation and CCM clinical lesions. The proteomic profile for each cell
line knockdown was unique; however, the most differentially expressed proteins were
cytoskeleton-associated proteins. Our analysis suggests that these proteins, in particular
MYH-9, may link CCM genes to dysregulation of actin–tubulin stability, and in turn cell–
cell interaction leading to CCM lesions. Our systems biology analyses demonstrate the
potential role of CCM proteins in signaling pathways linking the VEGF signaling, actin-
mediated signaling, cell function and cell–cell interaction. However, the preliminary data
will require future functional study of the proteins in each signaling pathway to definitively
answer the role of CCM proteins in endothelial differentiation and CCM development. We
also recognize that the limitation of our in vitro system may alter the cellular signaling. This
further supports the need for future confirmative study of these proteins in cells and in
animal models. In the future, CCM-related proteins may be utilized as biomarkers for CCM
or used to reverse engineering the CCM signaling pathway for therapy purposes.
Edelmann et al. Page 7























Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
S Bencharit was supported by the National Heart, Lung and Blood Institute NHLBI, NIH Grant R21HL092338 and
the University of North Carolina at Chapel Hill Junior Faculty Development Award. The authors thank GL Johnson
and his laboratory for providing experimental assistance. The authors also thank K Knagge and the PRIDE team in
the assistance for the data deposition [45].
References
1. Zhang J, Clatterbuck RE, Rigamonti D, Dietz HC. Mutations in KRIT1 in familial cerebral
cavernous malformations. Neurosurgery. 2000; 46(5):1272–1277. discussion 1277–1279. [PubMed:
10807272]
2. Rigamonti D, Hadley MN, Drayer BP, et al. Cerebral cavernous malformations. Incidence and
familial occurrence. N Engl J Med. 1988; 319(6):343–347. [PubMed: 3393196]
3. Russell, DS.; Rubinstein, LJ. Pathology of tumours of the nervous system. Baltimore, MD, USA:
Williams & Wilkins; 1989.
4. Robinson JR, Awad IA, Little JR. Natural history of the cavernous angioma. J Neurosurg. 1991;
75(5):709–714. [PubMed: 1919692]
5. Zabramski JM, Henn JS, Coons S. Pathology of cerebral vascular malformations. Neurosurg Clin N
Am. 1999; 10(3):395–410. [PubMed: 10419567]
6. Bergametti F, Denier C, Labauge P, et al. Mutations within the programmed cell death 10 gene
cause cerebral cavernous malformations. Am J Hum Genet. 2005; 76(1):42–51. [PubMed:
15543491]
7. Craig HD, Gunel M, Cepeda O, et al. Multilocus linkage identifies two new loci for a Mendelian
form of stroke, cerebral cavernous malformation, at 7p15-13 and 3q25.2-27. Hum Mol Genet. 1998;
7(12):1851–1858. [PubMed: 9811928]
8. Dubovsky J, Zabramski JM, Kurth J, et al. A gene responsible for cavernous malformations of the
brain maps to chromosome 7q. Hum Mol Genet. 1995; 4(3):453–458. [PubMed: 7795602]
9. Dupre N, Verlaan DJ, Hand CK, et al. Linkage to the CCM2 locus and genetic heterogeneity in
familial cerebral cavernous malformation. Can J Neurol Sci. 2003; 30(2):122–128. [PubMed:
12774951]
10. Guclu B, Ozturk AK, Pricola KL, et al. Mutations in apoptosis-related gene, PDCD10, cause
cerebral cavernous malformation 3. Neurosurgery. 2005; 57(5):1008–1013. [PubMed: 16284570]
11. Liquori CL, Berg MJ, Siegel AM, et al. Mutations in a gene encoding a novel protein containing a
phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. Am J Hum
Genet. 2003; 73(6):1459–1464. [PubMed: 14624391]
12. Borikova AL, Dibble CF, Sciaky N, et al. Rho kinase inhibition rescues the endothelial cell
cerebral cavernous malformation phenotype. J Biol Chem. 2010; 285(16):11760–11764. [PubMed:
20181950]
13. Sahoo T, Johnson EW, Thomas JW, et al. Mutations in the gene encoding KRIT1, a Krev-1/rap1a
binding protein, cause cerebral cavernous malformations (CCM1). Hum Mol Genet. 1999; 8(12):
2325–2333. [PubMed: 10545614]
14. Serebriiskii I, Estojak J, Sonoda G, et al. Association of Krev-1/rap1a with KRIT1, a novel ankyrin
repeat-containing protein encoded by a gene mapping to 7q21-22. Oncogene. 1997; 15(9):1043–
1049. [PubMed: 9285558]
15. Zhang J, Clatterbuck RE, Rigamonti D, et al. Interaction between KRIT1 and icap1alpha infers
perturbation of integrin beta1-mediated angiogenesis in the pathogenesis of cerebral cavernous
malformation. Hum Mol Genet. 2001; 10(25):2953–2960. [PubMed: 11741838]
Edelmann et al. Page 8






















16. Uhlik MT, Abell AN, Johnson NL, et al. Rac-MEKK3-MKK3 scaffolding for p38 MAPK
activation during hyperosmotic shock. Nat Cell Biol. 2003; 5(12):1104–1110. [PubMed:
14634666]
17. Zawistowski JS, Stalheim L, Uhlik MT, et al. CCM1 and CCM2 protein interactions in cell
signaling: implications for cerebral cavernous malformations pathogenesis. Hum Mol Genet. 2005;
14(17):2521–2531. [PubMed: 16037064]
18. Crose LE, Hilder TL, Sciaky N, Johnson GL. Cerebral cavernous malformation 2 protein promotes
smad ubiquitin regulatory factor 1-mediated RhoA degradation in endothelial cells. J Biol Chem.
2009; 284(20):13301–13305. [PubMed: 19318350]
19. Chen L, Tanriover G, Yano H, et al. Apoptotic functions of PDCD10/CCM3, the gene mutated in
cerebral cavernous malformation 3. Stroke. 2009; 40(4):1474–1481. [PubMed: 19246713]
20. Zhang H, Ma X, Deng X, et al. PDCD10 interacts with STK25 to accelerate cell apoptosis under
oxidative stress. Front Biosci. 2012; 17:2295–2305.
21. Gordon J, Hwang J, Carrier KJ, et al. Protein phosphatase 2a (PP2A) binds within the
oligomerization domain of striatin and regulates the phosphorylation and activation of the
mammalian Ste20-Like kinase Mst3. BMC Biochem. 2011; 12:54. [PubMed: 21985334]
22. Fidalgo M, Guerrero A, Fraile M, et al. Adaptor protein cerebral cavernous malformation 3
(CCM3) mediates phosphorylation of the cytoskeletal proteins ezrin/radixin/moesin by
mammalian Ste20-4 to protect cells from oxidative stress. J Biol Chem. 2012; 287(14):11556–
11565. [PubMed: 22291017]
23. Dibble CF, Horst JA, Malone MH, et al. Defining the functional domain of programmed cell death
10 through its interactions with phosphatidylinositol-3,4,5-trisphosphate. PLoS One. 2010;
5(7):e11740. [PubMed: 20668527]
24. ProteomeXchange. Available from: http://proteomecentral.proteomexchange.org.
25. Peddinti D, Memili E, Burgess SC. Proteomics-based systems biology modeling of bovine
germinal vesicle stage oocyte and cumulus cell interaction. PLoS One. 2010; 5(6):e11240.
[PubMed: 20574525]
26. Gerling IC, Singh S, Lenchik NI, et al. New data analysis and mining approaches identify unique
proteome and transcriptome markers of susceptibility to autoimmune diabetes. Mol Cell
Proteomics. 2006; 5(2):293–305. [PubMed: 16227630]
27. Huang Y, Yan J, Lubet R, et al. Identification of novel transcriptional networks in response to
treatment with the anticarcinogen 3H-1,2-dithiole-3-thione. Physiol Genomics. 2006; 24(2):144–
153. [PubMed: 16317079]
28. Hilder TL, Malone MH, Bencharit S, et al. Proteomic identification of the cerebral cavernous
malformation signaling complex. J Proteome Res. 2007; 6(11):4343–4355. [PubMed: 17900104]
29. Bunai F, Ando K, Ueno H, Numata O. Tetrahymena eukaryotic translation elongation factor 1A
(eEF1A) bundles filamentous actin through dimer formation. J Biochem. 2006; 140(3):393–399.
[PubMed: 16877446]
30. Liu G, Tang J, Edmonds BT, et al. F-actin sequesters elongation factor 1alpha from interaction
with aminoacyl-tRNA in a pH-dependent reaction. J Cell Biol. 1996; 135(4):953–963. [PubMed:
8922379]
31. Ejiri S. Moonlighting functions of polypeptide elongation factor 1: from actin bundling to zinc
finger protein R1-associated nuclear localization. Biosci Biotechnol Biochem. 2002; 66(1):1–21.
[PubMed: 11866090]
32. Seo S, Baye LM, Schulz NP, et al. BBS6, BBS10, and BBS12 form a complex with CCT/TRiC
family chaperonins and mediate BBSome assembly. Proc Natl Acad Sci USA. 2010; 107(4):1488–
1493. [PubMed: 20080638]
33. Assinder SJ, Stanton JA, Prasad PD. Transgelin: an actin-binding protein and tumour suppressor.
Int J Biochem Cell Biol. 2009; 41(3):482–486. [PubMed: 18378184]
34. Keshamouni VG, Jagtap P, Michailidis G, et al. Temporal quantitative proteomics by iTRAQ 2D-
LC-MS/MS and corresponding mRNA expression analysis identify post-transcriptional
modulation of actin-cytoskeleton regulators during TGF-beta-Induced epithelial-mesenchymal
transition. J Proteome Res. 2009; 8(1):35–47. [PubMed: 19118450]
Edelmann et al. Page 9






















35. Alexander JS, Minagar A, Harper M, et al. Proteomic analysis of human cerebral endothelial cells
activated by multiple sclerosis serum and IFNbeta-1b. J Mol Neurosci. 2007; 32(3):169–178.
[PubMed: 17873362]
36. Huang Y, Shi H, Zhou H, et al. The angiogenic function of nucleolin is mediated by vascular
endothelial growth factor and nonmuscle myosin. Blood. 2006; 107(9):3564–3571. [PubMed:
16403913]
37. Schneider H, Errede M, Ulrich NH, et al. Impairment of tight junctions and glucose transport in
endothelial cells of human cerebral cavernous malformations. J Neuropathol Exp Neurol. 2011;
70(6):417–429. [PubMed: 21572340]
38. Baev NI, Awad IA. Endothelial cell culture from human cerebral cavernous malformations. Stroke.
1998; 29(11):2426–2434. [PubMed: 9804658]
39. Olk S, Turchinovich A, Grzendowski M, et al. Proteomic analysis of astroglial connexin43
silencing uncovers a cytoskeletal platform involved in process formation and migration. Glia.
2010; 58(4):494–505. [PubMed: 19795503]
40. Glading A, Han J, Stockton RA, Ginsberg MH. KRIT-1/CCM1 is a Rap1 effector that regulates
endothelial cell–cell junctions. J Cell Biol. 2007; 179(2):247–254. [PubMed: 17954608]
41. Dejana E, Tournier-Lasserve E, Weinstein BM. The control of vascular integrity by endothelial
cell junctions: molecular basis and pathological implications. Dev Cell. 2009; 16(2):209–221.
[PubMed: 19217423]
42. Gore AV, Lampugnani MG, Dye L, et al. Combinatorial interaction between CCM pathway genes
precipitates hemorrhagic stroke. Dis Model Mech. 2008; 1(4–5):275–281. [PubMed: 19093037]
43. Whitehead KJ, Chan AC, Navankasattusas S, et al. The cerebral cavernous malformation signaling
pathway promotes vascular integrity via Rho GTPases. Nat Med. 2009; 15(2):177–184. [PubMed:
19151728]
44. Gault J, Awad IA, Recksiek P, et al. Cerebral cavernous malformations: somatic mutations in
vascular endothelial cells. Neurosurgery. 2009; 65(1):138–144. discussion 144-135. [PubMed:
19574835]
45. Vizcaino JA, Cote RG, Csordas A, et al. The proteomics identifications (PRIDE) database and
associated tools: status in 2013. Nucleic Acids Res. 2013; 41:D1063–D1069. (Database issue).
[PubMed: 23203882]
Edelmann et al. Page 10























• Biology of cerebral cavernous malformations (CCM) lesion development is not
clear.
• Proteomic global analysis of CCM gene knockdown has not been done.
• Application of label-free differential protein expression analysis to a CCM
knockdown human cell line has not been reported.
• There is currently no systems biology analysis available for CCM.
• Elucidating the biology of CCM lesions may lead to a novel biomarker-based
diagnosis.
• Early intervention of CCM lesions may prevent further lost of function.
• The proteins associated with specific CCM gene knockdown allow novel insight
into CCM lesion development and therapy.
• Proteomic profiling and systems biology analysis may be an important tool to
examine CCM in vitro and in humans.
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Figure 1. Proteomic analysis
(A–C) The knockdown effects of CCM1, CCM2 and CCM3 genes; (D) principal component
analysis at p < 0.005; (E) principal component analysis at p < 0.001; (F) cluster analysis at p
< 0.005 and (G) cluster analysis at p < 0.001.
CCM: Cerebral cavernous malformations; EF1G: Elongation factor 1γ.
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Figure 2. Western blot analysis showing myosin-9 and elongation factor 1γ of the knockdowns;
CCM1, CCM2 and CCM3 compared with the wild-type and mock knockdown
CCM: Cerebral cavernous malformations.
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Figure 3. VEGF-related signaling based on ingenuity pathways analysis
(A) mTOR signaling; (B) P13K/AKT signaling; (C) VEGF signaling.
CCM: Cerebral cavernous malformations.
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Figure 4. Actin-related signaling based on ingenuity pathways analysis
(A) Acting cytoskeleton signaling; (B) regulation of actin-based motility by Rho.
CCM: Cerebral cavernous malformations.
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Figure 5. Epithelial junction-related signaling based on ingenuity pathways analysis
(A) Remodeling of epithelial adherens junctions; (B) germ cell-Sertoli cell junction
signaling; (C) epithelial adherens junction signaling; (D) Sertoli cell-Sertoli cell junction
signaling; (E) Tight junction signaling.
CCM: Cerebral cavernous malformations.
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Figure 6. Proposed model of cerebral cavernous malformations development
KRIT1: Krev interaction trapped 1; MYH9: Myosin-9; OSM: Osmosensing scaffold for
MEKK3; PDCD10: Programmed cell death 10.
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Table 1




Function Role in CCM
EF1α The 2nd most abundant protein in the body and is
multifunctional. Its primary purpose is the elongation of
polypeptides through catalyzing GTP-dependent binding
of aminoacyl-tRNAs to their respective mRNA
anticodons [29]. It is also involved in the arrangement of
the actin cytoskeleton. EF1A as a translation component,
has a significant impact on actin- and tubulin-based
polymers in cells due to its abundance and relative high
affinity (1:3 molar ratio and a kd = 0.1 µm2) [30]. It
associates with the actin cytoskeleton and serves as an
activator for phosphatidylinositol 4-kinase. This
metabolite regulates phosphotidyl 4-phosphate and
phosphatidylinositol 4,5 biphosphate, which regulates
actin filaments via capping and severing. Thus, EF1A
may regulate the actin cytoskeleton through the
phosphoinositide signaling pathway. Its importance in
mRNA translation has been shown in previous studies; as
mRNA levels for EF1A directly increase in correlation
with increasing amount of rapidly proliferating cells in
human tumors [30]
EF1A was shown to interact directly with the CCM protein
complex [28]. CCM proteins such as osmosensing scaffold for
MEKK3 and programmed cell death 10 selectively bind to certain
phosphotidylinositol phosphates [23]. CCM proteins therefore can
regulate actin–tubulin formation through its interaction with EF1A
[28] as well as phosphotidylinositol phosphates [23]
EF1G EF1G is a differentially expressed protein, is also a
subunit of the EF1 complex that is responsible for the
enzymatic delivery of aminoacyl-tRNAs to the ribosome.
The subunit’s function has recently been discovered to be
involved in glutathione S-transferase activity [31]
Our proteomic analysis suggested that another elongation factor,
while it is clear that CCM complex interacts directly with EF1A, it
is likely that knockdown of CCM genes also affects other EF1
proteins such as EF1G [28]. However, the western blot analysis of
EF1G fails to show differential expression of this protein among
our cell lines (Figure 2). This could be explained by the limitations
of a western blot, which arise if the protein has been modified in
anyway. In addition, mass spectrometry recognizes a fragment of a
protein at a minute concentration, while western blot analysis




Molecular chaperone that is known to assist in the folding
of actin and tubulin [32]. T complex protein 1γ is
encoded by the gene CCT3 and is also a subunit of the
molecular chaperone, TCP1 complex
It is possible that CCM knockdown disrupts normal actin–tubulin
interaction and in turn activates the T complex pathway. It is
currently unknown if CCM genes regulate the T complex directly.
The stability of CCM complex may also temporally stabilize the
actin–tubulin complex. Therefore, knockdown of a CCM gene
would destabilize the CCM and actin–tubulin complex and result
in alteration of the expression of actin–tubulin chaparones
Transgelin An actin-binding protein and a tumor suppressor. It is
believed that it functions as a smooth cell differentiator
that regulates the contractile properties of smooth muscle
cells. In cancerous cells, expression of transgelin is
decreased through the activation of the Ras-MEK-ERK-
myc signaling pathway
This results in a disorganized cytoskeleton of actin filaments, a key
trait in cancerous phenotypes. This is due to an inability of the
transgelin protein to cross-link with actin [33]. CCM knockdown
can dysregulate actin-stabilizing proteins such as cofilin.
Interestingly, cofilin knockdown in endothelial cells results in
similar alteration of transgelin expression [34]
MYH-9 MYH-9 is a subunit of myosin IIA protein, the protein
complex has multiple roles including the maintenance of
cell shape
A cytoskeleton protein had the most differential protein expression
among the five cell lines in both proteomic and western blot
analysis (Figure 2). MYH-9 protein cell line knockdown of each
CCM genes resulted in differential expression in comparison with
the two control groups (wild type and mock). Another proteomic
analysis has identified MYH-9 as a target in human cerebral
endothelial cells [35]. MYH-9 is a main regulator for endothelial
gap formation [36]. It is interesting to note that CCM lesions in
humans have defects in endothelial tight junctions, which may
contribute to cerebral hemorrhage [36]
CCM: Cerebral cavernous malformations; EF1A: Elongation factor 1α; EF1G: Elongation factor 1γ; MYH-9: Myosin-9.
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